Clean Sweep Live Auction on Thur. March 28th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment



Rad Oncology Homepage

Four considerations before embarking on a carbon therapy center The next frontier in improving cancer care

Q & A with Scott Warwick, executive director of the National Association for Proton Therapy Find out what to expect at the year's biggest proton therapy industry event

New approach identifies lung cancer patients most likely to respond to chemotherapy Combines radiomics and CT image assessment

Aussies and Americans develop 3D models for assessing impacts of radiotherapy Test different levels and types of radiation

Law in Ontario prevents cremation of brachytherapy patients Experts call for eliminating the law, as it deters patients from lifesaving treatment

IBA tech plays first-time role in flash therapy demonstration Supports eventual integration of flash as clinical treatment

Access to proton therapy increasing for pediatric patients Young cancer patients have the most to gain from proton treatment

Public-private partnership replaces 50-year old radiotherapy equipment in Guatemala Upgrading to Varian Halcyon system

Hypofractionated radiotherapy no worse than conventional RT, says study No difference in progression and survival

Proton therapy market continues decline after 2015 high point: report By comparison, investment in 2018 dropped 62 percent

Ultrasound aids in delivery of brachytherapy in prostate cancer patients

by John W. Mitchell , Senior Correspondent
Physicians at a Spanish hospital reported their success in treating men with prostate cancer in one ultrasound-guided outpatient radiation session, rather than several lower dose treatments.

Patients report they prefer the one-time brachytherapy treatment. They did not experience any worse side effects compared to the standard multiple-treatment protocol or need to return to the hospital at a greater frequency.

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

"There is a great interest in the prostate cancer field to try to reduce treatment times, avoid toxicity and maintain quality of life for the patient," Dr. Alfonso Gomez-Iturriaga, with the Department of Radiation Oncology at Hospital Universitario Cruces Bizkaia in Spain, told HCB News. "Of note, [the one dose treatment] is done as an outpatient procedure. Patients come to the hospital in the morning and go back home at evening with the treatment of the prostate cancer done."

The findings were reported at the ESTRO 36 conference in Vienna, an interdisciplinary meeting of radiation oncologists, medical physicists, radiobiologists, brachytherapists, and radiologists.

In the study, 45 consecutive men received HDR brachytherapy over an 18-month period ending in July 2016. The patients had low- or intermediate-risk prostate cancer, with moderate symptoms and had not yet had other treatments, such as surgery. The median follow-up time for the patients was 16 months. No adverse side effects were reported, other than a half dozen cases of moderate bowel (diarrhea) or bladder (frequency) problems.

"So far, the results are good, but it is too soon to talk about cancer control," said Gomez-Iturriaga. "We have to wait at least three years more to find out how efficacious this novel treatment is. It is also unknown whether the dose administered in our trial is enough or we have to increase the dose in the future."

HDR brachytherapy involves the very precise positioning of catheters, with the aid of ultrasound, at the site of the tumor while the patient is under spinal or general anesthetic. A radioactive source (iridium-192) is delivered via the catheters to the target, avoiding other organs such as the bladder and the bowel. The treatment usually takes about 30 minutes.

According to Gomez-Iturriaga, the treatment involves real-time 3-D visualization of the target with the ultrasound. All of this, he explained, allows for extraordinary control over the dose administration.

"Our study has demonstrated (this method) to be safe and great for maintaining quality of life," he said. "But it is too soon to know if it is as curative as other treatments such as IMRT or seed brachytherapy."

Back to HCB News
  Pages: 1

Rad Oncology Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.